This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.

Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

  • Products
  • Therapy Areas
  • Resources
  • Events & Webinars
  • Learning Zone
  • Podcasts
Kerendia®▼ (finerenone) is indicated for the treatment of chronic kidney disease (Stages 3 and 4 with albuminuria) associated with type 2 diabetes in adult patients.

Managing the progression of Chronic Kidney Disease in Type 2 Diabetes

Kerendia®▼ (finerenone) is the first and only selective, non-steroidal mineralocorticoid receptor (MR) antagonist licensed to treat CKD associated with Type 2 Diabetes
1

HCP Hub headerv4

Managing the progression of CKD in T2D

Uncontrolled diabetes and hypertension are major causes of Chronic Kidney Disease in the UK
1

image-20231106-162711

Kerendia targets the mineralocorticoid receptor (MR)
8

There is a growing body of evidence that MR overactivation leads to inflammation and fibrosis and is a key driver of CKD progression9

Kerendia is a selective, non-steroidal MR antagonist9

 

Drug classes used in the management of CKD associated with T2D

Drug classes used in the management of Chronic Kidney Disease associated with T2D

Please see '

Safety profile'
section for information on hypotension and blood pressure reduction observed with Kerendia.

*SBP baseline to month 1 and month 12, -3.0 and -2.1 mm Hg respectively with finerenone and -0.1 and 0.9 mm Hg, respectively with placebo.

**Adverse reactions occurring in >1% of patients includes hypotension; the risk increases with concomitant use of multiple other antihypertensive medicines. For additional information relating to effects of Kerendia on blood pressure see safety section.

Not all treatments used to control blood pressure and T2D are indicated for the management of CKD associated with T2D. Please consult the relevant SmPC before using any pharmacological treatment. Bayer does not encourage the use of any medicine out of its licensed indication.

Kerendia is the only licensed and NICE approved ns-MRA in UK for the treatment of patients with CKD (stages 3 & 4 with albuminuria) associated with type 2 diabetes8

Steroidal vs non-steroidal

Download our guide to learn more on how 

Kerendia® a non-steroidal MRA, is distinct from steroidal MRAs

 

Steroidal vs Non-Steroidal Download

Kerendia provides HCPs with an additional treatment option to help delay Chronic Kidney Disease progression in patients with Type 2 Diabetes
8

Kerendia is pharmacologically distinct from steroidal MRAs
11

Kerendia is pharmacologically distinct from steroidal MRAs
11

image-20231106-162855

Adapted from Kolkhof11

**Statements are based on preclinical data and are not supported by human studies

 

Kerendia has not been compared to currently available MRAs in Phase 3 clinical trials; therefore, the clinical consequences of differences between the characteristics described is unknown.

In vitro, Kerendia is ≥500-fold more selective for the MR than for glucocorticoid, androgen, progesterone or oestrogen receptors (vs. ~3-fold for spironolactone)12,13

 

Kerendia has a short half-life (2–3 hours in patients with CKD) and no active metabolites. Hyperkalaemia is a listed as a very common side effect of kerendia affecting ≥ 1/10 of patients. In the FIDELIO-DKD study, finerenone associated hyperkalaemia was most frequently managed by treatment interruption. For additional information please see safety & dosing section of the website.8

Read about the FIDELIO-DKD trial design
    1. Kidney Care UK. Available at: www.kidneycareuk.org/news-and-campaigns/facts-and-stats/?gclid=EAlalQobChMl7tm8gfqp9QlVkoBQBh2iGAxyEAAYB-CAAEgJTOvD_BwE. Last accessed March 2024.
    2. Alicic RZ, et al. Clin J Am Soc Nephrol. 2017;12(12):2032–2045.
    3. Mora-Fernández C, et al. J Physiol. 2014;592(18):3997–4012.
    4. Barrera-Chimal J, et al. Brit J Pharmacol. 2021; Epub ahead of print (DOI:10.1111/bph.15734).
    5. Bakris GL, et al. Am J Nephrol. 2019;50(5):333–344.
    6. Perkovic V, et al. N Engl J Med. 2019;380(24):2295–2306.
    7. Barrera-Chimal J, et al. Nat Rev Nephrol. 2022;18(1):56–70.
    8. UK Kerendia SmPC
    9. Agarwal R, et al. Nephrol Dial Transplant. 2020; Epub ahead of print (DOI:10.1093/ndt/gfaa294).
    10. Bakris GL, et al. N Engl J Med. 2020;383(23):2219–2229.
    11. Kolkhof P, et al. Handb Exp Pharmacol. 2017;243:271–305.
    12. Kolkhof P, et al. Pharmacol Res. 2021;172:105859.
    13. Pitt B, et al. Eur J Heart Fail. 2012;14(6):668–675.
    14. Agarwal A, et al. J Am Soc Nephrol. 2022;33(1):225–237.
    15. UK Aldactone SmPC
    16. UK Inspra SmPC

BP=blood pressure; CKD=chronic kidney disease; DKD=diabetic kidney disease; HCP=healthcare professional; MOD=mechanism of disease; MOA=mechanism of action; MR=mineralocorticoid receptor; MRA=mineralocorticoid receptor antagonist; ns-MRA=nonsteroidal mineralocorticoid receptor antagonist RAS=renin-angiotensin system; T2D=type 2 diabetes.

PP-KER-GB-0809 | June 2025